Cedric is CEO and member of the Board of Directors of myNEO. This Belgian-based biotech company identifies novel immunotherapies against personalised or proprietary tumour peptides (neoantigens). Its preclinical & clinical developments have been enabled by a digital platform mapping the interaction of a patient’s tumour and immune system. The team raised its capital from the Novalis biotech fund, and has closed several partnerships with major biopharma companies to further clinically develop its targets.
Prior to myNEO, Cedric was part of different ventures investigating oncology diagnostics (nutri-epigenomics), and computational advancements in genomic fingerprinting. He earned a Masters in Bioengineering and Medical Genetics from Ghent University, and was part of the Life Sciences Industry Group at Accenture Consulting.